United States Protein Identification Market By Product & Services (Consumables, Instruments, Services), By Application (Drug Discovery & Development, Clinical Diagnosis, Others), By End-Use (Pharmaceuticals & Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F
Market Overview
The United States Protein Identification Market was valued at USD 935.15 Million in 2024 and is projected to reach USD 1526.12 Million by 2030, expanding at a CAGR of 8.48% during the forecast period. The market is witnessing strong growth due to rising emphasis on molecular-level disease understanding and the need for accurate protein characterization in biomedical research. Protein identification is vital in studying protein structure, function, and expression, which supports the development of diagnostics, targeted therapies, and drug efficacy assessments. The increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions is accelerating demand for proteomic technologies.
With an estimated 1.9 million new cancer cases in the U.S. in 2023, the urgency for protein-based diagnostics is growing. Institutions and pharmaceutical companies are heavily investing in high-throughput proteomics and functional protein analysis tools. The widespread adoption of next-generation sequencing and advanced mass spectrometry platforms is also contributing significantly to the market’s expansion.
Key Market Drivers
Rising Demand for Biologics and Biosimilars
A key driver of the United States Protein Identification Market is the increasing demand for biologics and biosimilars. These therapies—including monoclonal antibodies, therapeutic proteins, and vaccines—are playing a transformative role in treating cancer, autoimmune diseases, and rare genetic conditions. Accurate protein characterization is essential for ensuring the safety, efficacy, and consistency of biologics.
In 2023, the FDA approved 55 new drugs, with 17 classified as biologics, including 12 monoclonal antibodies. Additionally, the Center for Biologics Evaluation and Research (CBER) approved 23 new biologics license applications, signaling robust growth in biologics development. This upward trend in approvals emphasizes the expanding reliance on protein identification technologies to support regulatory compliance and therapeutic success.
Key Market Challenges
High Cost of Instruments and Analytical Services
The high cost associated with instruments and analytical services poses a significant challenge for the U.S. Protein Identification Market. Essential tools such as mass spectrometers, chromatography systems, and protein analyzers come with substantial capital and operational expenses. These costs can be prohibitive for smaller research labs and academic institutions with limited budgets.
Beyond equipment investment, maintaining these systems demands trained personnel, regular servicing, and ongoing spending on specialized reagents and consumables. For organizations without adequate funding or reimbursement structures, these financial burdens can restrict the frequency and scope of protein analysis, limiting innovation and broader adoption of advanced techniques.
Key Market Trends
Rise in Monoclonal Antibody and Biologics Development
A significant trend shaping the market is the rising focus on monoclonal antibody and biologics development. As biologic therapies become increasingly central to modern medicine, precise protein identification is essential for validating molecular structure, function, and therapeutic behavior.
Advanced proteomic tools like mass spectrometry and chromatography are in growing demand to ensure quality control and regulatory compliance in drug development. The emphasis on personalized medicine and the complexity of biologics—where even minor structural differences can affect therapeutic outcomes—are reinforcing the need for robust protein identification platforms. Pharmaceutical companies and researchers are investing in next-generation solutions to meet these evolving requirements, thereby supporting market growth.
Key Market Players
Report Scope:
In this report, the United States Protein Identification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United States Protein Identification Market.
Available Customizations:
United States Protein Identification Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The United States Protein Identification Market was valued at USD 935.15 Million in 2024 and is projected to reach USD 1526.12 Million by 2030, expanding at a CAGR of 8.48% during the forecast period. The market is witnessing strong growth due to rising emphasis on molecular-level disease understanding and the need for accurate protein characterization in biomedical research. Protein identification is vital in studying protein structure, function, and expression, which supports the development of diagnostics, targeted therapies, and drug efficacy assessments. The increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions is accelerating demand for proteomic technologies.
With an estimated 1.9 million new cancer cases in the U.S. in 2023, the urgency for protein-based diagnostics is growing. Institutions and pharmaceutical companies are heavily investing in high-throughput proteomics and functional protein analysis tools. The widespread adoption of next-generation sequencing and advanced mass spectrometry platforms is also contributing significantly to the market’s expansion.
Key Market Drivers
Rising Demand for Biologics and Biosimilars
A key driver of the United States Protein Identification Market is the increasing demand for biologics and biosimilars. These therapies—including monoclonal antibodies, therapeutic proteins, and vaccines—are playing a transformative role in treating cancer, autoimmune diseases, and rare genetic conditions. Accurate protein characterization is essential for ensuring the safety, efficacy, and consistency of biologics.
In 2023, the FDA approved 55 new drugs, with 17 classified as biologics, including 12 monoclonal antibodies. Additionally, the Center for Biologics Evaluation and Research (CBER) approved 23 new biologics license applications, signaling robust growth in biologics development. This upward trend in approvals emphasizes the expanding reliance on protein identification technologies to support regulatory compliance and therapeutic success.
Key Market Challenges
High Cost of Instruments and Analytical Services
The high cost associated with instruments and analytical services poses a significant challenge for the U.S. Protein Identification Market. Essential tools such as mass spectrometers, chromatography systems, and protein analyzers come with substantial capital and operational expenses. These costs can be prohibitive for smaller research labs and academic institutions with limited budgets.
Beyond equipment investment, maintaining these systems demands trained personnel, regular servicing, and ongoing spending on specialized reagents and consumables. For organizations without adequate funding or reimbursement structures, these financial burdens can restrict the frequency and scope of protein analysis, limiting innovation and broader adoption of advanced techniques.
Key Market Trends
Rise in Monoclonal Antibody and Biologics Development
A significant trend shaping the market is the rising focus on monoclonal antibody and biologics development. As biologic therapies become increasingly central to modern medicine, precise protein identification is essential for validating molecular structure, function, and therapeutic behavior.
Advanced proteomic tools like mass spectrometry and chromatography are in growing demand to ensure quality control and regulatory compliance in drug development. The emphasis on personalized medicine and the complexity of biologics—where even minor structural differences can affect therapeutic outcomes—are reinforcing the need for robust protein identification platforms. Pharmaceutical companies and researchers are investing in next-generation solutions to meet these evolving requirements, thereby supporting market growth.
Key Market Players
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Eurofins Scientific
- Merck KGAA
- Promega Corporation
- Qiagen N.V.
- Sartorius AG
Report Scope:
In this report, the United States Protein Identification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- United States Protein Identification Market, By Product & Services:
- Consumables
- Instruments
- Services
- United States Protein Identification Market, By Application:
- Drug Discovery & Development
- Clinical Diagnosis
- Others
- United States Protein Identification Market, By End-Use:
- Pharmaceuticals & Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
- United States Protein Identification Market, By Region:
- North-East
- Mid-West
- West
- South
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United States Protein Identification Market.
Available Customizations:
United States Protein Identification Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES PROTEIN IDENTIFICATION MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Services (Consumables, Instruments, Services)
5.2.2. By Application (Drug Discovery & Development, Clinical Diagnosis, Others)
5.2.3. By End-Use (Pharmaceuticals & Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH-EAST PROTEIN IDENTIFICATION MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Services
6.2.2. By Application
6.2.3. By End-Use
7. MID-WEST PROTEIN IDENTIFICATION MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Services
7.2.2. By Application
7.2.3. By End-Use
8. WEST PROTEIN IDENTIFICATION MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Services
8.2.2. By Application
8.2.3. By End-Use
9. SOUTH PROTEIN IDENTIFICATION MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Services
9.2.2. By Application
9.2.3. By End-Use
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS
13. POLICY & REGULATORY LANDSCAPE
14. UNITED STATES ECONOMIC PROFILE
15. UNITED STATES PROTEIN IDENTIFICATION MARKET: SWOT ANALYSIS
16. PORTER’S FIVE FORCES ANALYSIS
16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products
17. COMPETITIVE LANDSCAPE
17.1. Agilent Technologies, Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Bio-Rad Laboratories, Inc.
17.3. Bruker Corporation
17.4. Thermo Fisher Scientific Inc.
17.5. Danaher Corporation
17.6. Eurofins Scientific
17.7. Merck KGAA
17.8. Promega Corporation
17.9. Qiagen N.V.
17.10. Sartorius AG
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES PROTEIN IDENTIFICATION MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Services (Consumables, Instruments, Services)
5.2.2. By Application (Drug Discovery & Development, Clinical Diagnosis, Others)
5.2.3. By End-Use (Pharmaceuticals & Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH-EAST PROTEIN IDENTIFICATION MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Services
6.2.2. By Application
6.2.3. By End-Use
7. MID-WEST PROTEIN IDENTIFICATION MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Services
7.2.2. By Application
7.2.3. By End-Use
8. WEST PROTEIN IDENTIFICATION MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Services
8.2.2. By Application
8.2.3. By End-Use
9. SOUTH PROTEIN IDENTIFICATION MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Services
9.2.2. By Application
9.2.3. By End-Use
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS
13. POLICY & REGULATORY LANDSCAPE
14. UNITED STATES ECONOMIC PROFILE
15. UNITED STATES PROTEIN IDENTIFICATION MARKET: SWOT ANALYSIS
16. PORTER’S FIVE FORCES ANALYSIS
16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products
17. COMPETITIVE LANDSCAPE
17.1. Agilent Technologies, Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Bio-Rad Laboratories, Inc.
17.3. Bruker Corporation
17.4. Thermo Fisher Scientific Inc.
17.5. Danaher Corporation
17.6. Eurofins Scientific
17.7. Merck KGAA
17.8. Promega Corporation
17.9. Qiagen N.V.
17.10. Sartorius AG
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
